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Background: Pulmonary fibrotic diseases induce significant morbidity and mortality, for which there are limited
therapeutic options available. Rac2, a ras-related guanosine triphosphatase expressed mainly in hematopoietic cells,
is a crucial molecule regulating a diversity of mast cell, macrophage, and neutrophil functions. All these cell types
have been implicated in the development of pulmonary fibrosis in a variety of animal models. For the studies
described here we hypothesized that Rac2 deficiency protects mice from bleomycin-induced pulmonary fibrosis.
Methods: To determine the role of Rac2 in pulmonary fibrosis we used a bleomycin-induced mouse model.
Anesthetized C57BL/6 wild type and rac2−/− mice were instilled intratracheally with bleomycin sulphate (1.25 U/
Kg) or saline as control. Bronchoalveolar lavage (BAL) samples were collected at days 3 and 7 of treatment and
analyzed for matrix metalloproteinases (MMPs). On day 21 after bleomycin treatment, we measured airway resistance
and elastance in tracheotomized animals. Lung sections were stained for histological analysis, while homogenates were
analyzed for hydroxyproline and total collagen content.
Results: BLM-treated rac2−/− mice had reduced MMP-9 levels in the BAL on day 3 and reduced neutrophilia and TNF
and CCL3/MIP-1α levels in the BAL on day 7 compared to BLM-treated WT mice. We also showed that rac2 −/− mice
had significantly lower mortality (30%) than WT mice (70%) at day 21 of bleomycin treatment. Lung function was
diminished in bleomycin-treated WT mice, while it was unaffected in bleomycin-treated rac2−/− mice. Histological
analysis of inflammation and fibrosis as well as collagen and hydroxyproline content in the lungs did not show
significant differences between BLM-treated rac2−/− and WT and mice that survived to day 21.
Conclusion: Rac2 plays an important role in bleomycin-induced lung injury. It is an important signaling molecule
leading to BLM-induced mortality and it also mediates the physiological changes seen in the airways after
BLM-induced injury.
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Fibrosis as a result of lung injury arising from various
known or unknown etiologies, carries a high rate of
morbidity and mortality [1]. Idiopathic pulmonary fibro-
sis is usually diagnosed at a late stage of disease, and
identification of the pathogenic steps leading to fibrosis
has met with limited success [2]. Various animal models
of fibrotic diseases have shown a role for inflammatory
cells, including macrophages and neutrophils, as well as* Correspondence: paige.lacy@ualberta.ca; hari@ualberta.ca
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free radicals [6,7].
One way of understanding the cellular and inflamma-
tory mechanisms associated with lung fibrosis has been
the intratracheal application of bleomycin (BLM), an
antineoplastic antibiotic, to induce a model of pulmonary
fibrosis in mice [8]. BLM-induced lung injury is charac-
terized by early recruitment of neutrophils followed by
extensive fibrosis that is self-limiting. Many other cells,
including mast cells and macrophages, have also been
implicated in establishing inflammation in this model.tral Ltd. This is an Open Access article distributed under the terms of the
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guanosine triphosphatase expressed primarily in hema-
topoietic cells, and is a crucial molecule regulating a
variety of neutrophil and macrophage functions [9-11].
Rac2 switches from a resting, inactive GDP-bound state
to an active GTP-bound state in response to receptor
stimulation. The GTP-bound form of Rac2 is essential
for activation of the superoxide-generating NADPH
oxidase complex in neutrophils [10] and is required for
exocytosis of primary azurophilic granules through
polymerization of F-actin filaments required for propel-
ling granules to the cell membrane [9,12]. Macrophages
utilize Rac2, in addition to the ubiquitously expressed
homolog Rac1, for maximal phagocytosis and oxidant
production [11]. Disruption of the gene encoding Rac2
led to attenuated lung inflammation and injury in a
model of immune complex-mediated acute lung injury
[13]. Diminished lung injury in rac2−/− mice with acute
lung injury was associated with decreased neutrophil
recruitment to the airways, reduced matrix metallopro-
teinase (MMP)-2 and −9 levels in bronchoalveolar lavage
samples, and decreased MMP-2 and −9 immunoreactivity
in airway and mucosal macrophages [13]. A small mol-
ecule inhibitor of Rac1 and Rac2 also alleviates LPS-
induced acute lung injury [14].
Since neutrophils and macrophages have been shown
to play an important role in the development of BLM-
induced fibrosis, we hypothesized that Rac2 deficiency
will protect mice from lung injury and fibrosis in
response to BLM administration.
Materials and methods
Animals
Rac2-deficient mice (rac2−/−) were established by gene
disruption [10] and were backcrossed for >11 genera-
tions on the C57BL/6 strain background. Rac2-deficient
mice were bred in our animal facility and housed under
specific virus antigen-free conditions on a 12:12-h light–
dark cycle and fed autoclaved food and water as needed.
Wild type (WT) C57BL/6 mice were purchased from
Charles River Laboratories and were housed and main-
tained in the same manner as rac2−/− mice. For our
experiments, we used female rac2−/− or C57BL/6 WT
mice at 10–14 wk of age. Animal experiments were
approved by the University of Alberta Health Sciences
Laboratory Animal Ethics Committee (Edmonton, AB,
Canada).
BLM-induced pulmonary fibrosis
After general anesthesia with 4% isoflurane inhalation,
the trachea was exposed and a single intratracheal
injection of BLM sulphate (0.125 U/100 g body weight
dissolved in normal saline, Sigma-Aldrich Co., MO, USA)
or saline as control was administrated to C57BL/6 WTand rac2−/− mice. Following the injection, mice were
sutured, allowed to recover and daily monitored for
morbidity and mortality.
Lung function measurements
On day 21 after BLM intratracheal instillation, mice
were weighed and lung function was measured. Each
mouse was anesthetized with 0.1 ml/10 g body weight of
a mixture containing xylazine (1.6 mg/ml; Bayer) and
ketamine (8 mg/ml; Parnell). Following anesthesia, a
tracheotomy was performed, and a polyethylene cannula
was inserted. Pancuronium amide (2 mg/kg) was admin-
istered intravenously before animals were attached to a
ventilator. Mice were mechanically ventilated on a com-
puted controlled piston ventilator FlexiVent® Systems
(SCIREQ, Montreal, QC, Canada) with a tidal volume of
5.5 ml/kg at a rate of 150 breaths/min.
Lung histology, αSMA and TGFβ analysis
On days 7 or 21 after BLM administration, left lungs
were cannulated, inflated with 10% neutral buffered for-
malin (Sigma-Aldrich, St. Louis, MO) for 5 min under a
constant pressure of 20 cm of H2O, removed from ani-
mals, and placed in fresh 10% neutral buffered formalin
for 24 h. In the case of the 21 day group, lung resection
was done after lung function testing. Tissues were then
embedded in paraffin blocks, and sections were cut
(4 μm) and stained with hematoxylin and eosin (H&E)
and periodic acid-Schiff-diastase stain (PAS-D). Staining
of lung sections with Masson’s trichrome, or with anti-
bodies for α-smooth muscle actin (αSMA) and TGFβ
were performed to obtain histological evidence of
fibrotic activity. Lung fibrosis was scored according to
Ashcroft’s criteria as previously published [15].
Bronchoalveolar lavage (BAL) and evaluation of cellular
infiltration, neutrophil myeloperoxidase (MPO) activity,
MMP and cytokine/chemokine levels
Mice were euthanized on days 3 and 7 after saline or
BLM intratracheal instillation. Following blood collec-
tion by cardiac puncture, the trachea was exposed and
intubated with a polyethylene catheter. Lungs were
lavaged twice with 1 ml of isotonic phosphate-buffered
saline (pH 7.4) and the bronchoalveolar lavage (BAL)
fluid was collected. The BAL fluid was centrifuged at
300 g for 5 min. Total cells in the resulting pellet were
counted, and cytospins of 5000 cells/sample were pre-
pared and stained with Diff-Quick (Fisher Scientific Co,
Kalamazoo, MI). Airway inflammation was assessed by
counting the number of inflammatory cells in the BAL
fluid as previously described [16]. BAL supernatants
were kept frozen in −80°C for MMP and MPO evalu-
ation. MMPs were evaluated by gelatin zymography as
previously described [17]. MPO activity was assessed
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previously described [9]. Cytokine and chemokine levels
were also evaluated in BAL fluid at day 7 after BLM
instillation.
Biochemical analysis of lung tissue
After lung function measurements, right lungs from
each animal were removed, weighed and immediately
frozen on liquid nitrogen and stored at −80°C for bio-
chemical analysis as described below.
Hydroxyproline determination was done as described
[18]. In brief, lung tissue was thawed and homogenized
in 1 ml of water. To precipitate protein, 125 μl of 50%
trichloroacetic acid (Sigma-Aldrich) was added to the
homogenate and samples were incubated on ice for
20 min. Samples were centrifuged at 300 g for 5 min at
4°C. Supernatants were discarded and 1 ml 12 N HCl
was added to the pellet. The pellet was baked at 110°C
for 24 h. The dried pellet was reconstituted with 2 ml of
distilled water and 500 μl of chloramine T solution (1.4%
chloramine T in 0.5 M sodium acetate and 10% isopro-
panol, Sigma-Aldrich) and incubated for 20 min at 24°C.
Ehrlich’s/pDMAB (1 M p-diamethylaminobenzaldehyde
in 70% isopropanol and 30% perchloric acid) was also
added and incubated at 65°C for 15 min. A sample of
100 μl of the final reaction solution was transferred to a
96-well plate, and the absorbance for each sample was
read at 550 nm in a Power Wave XS (BioTek Instru-
ments Inc., Winooski, VT) ELISA reader. The concen-
tration of lung hydroxyproline was calculated from a
hydroxyproline standard curve and expressed as μg/gram
of lung tissue.
The total collagen content of lungs was determined
using homogenized right lungs and a Sircol™ Soluble
Collagen Assay kit (Biocolor, Carrickfergus, UK) accord-
ing to manufacter’s instructions. Data are expressed as
the collagen content of the entire right lung.
Statistical analysis
Values are expressed as mean ± SEM. Statistical differ-
ences in the mean values among treatment groups were
determined by using a one-way ANOVA test with post-
hoc analysis using Tukey’s multiple comparison test. In
all cases, a value for p < 0.05 was considered statistically
significant.
Results
Rac2 mediates airway neutrophil infiltration and MMP-9
release in the airways following BLM-induced injury
Rac2 is expressed primarily in hematopoietic cells, and
has an important role in cell motility, superoxide
release and degranulation in neutrophils and macro-
phages [9,10,19]. Rac2 also mediates acute lung injury
due to immune complexes in murine models [13]. Theaim of this study was to understand the role of Rac2 in
BLM-induced lung injury, a model with a more prolonged
time course than immune complex-mediated injury. BLM
induces reversible fibrosis over 2–3 weeks; early accumu-
lation of neutrophils [20] and macrophages [21] has been
shown to be important for the transition from inflamma-
tion to fibrosis in this model.
To understand the role of Rac2 in BLM-induced lung
injury, we first examined the accumulation of inflamma-
tory cells and inflammatory mediators in the airways of
mice 3 and 7 days after induction of bleomycin-induced
lung injury. To do that we performed BAL on days 3
and 7 after BLM administration, and evaluated the num-
bers of neutrophils and macrophages, and the presence
of MPO, MMP-2 and MMP-9 activity, as well as cyto-
kine and chemokine levels.
BAL performed on day 3 showed no significant differ-
ences in total cells, neutrophils, macrophages or lym-
phocytes between BLM- and saline-treated mice in WT
and rac2−/− groups (Figure 1A-D, n = 5). WT mice re-
ceiving BLM showed accumulation of inflammatory cells
in the BAL on day 7 compared to saline-treated mice
(Figure 1A). In contrast, BLM-treated rac2−/− mice
showed no significant accumulation of cells in BAL on
day 7 (Figure 1A). While BLM induced the recruitment
of neutrophils to the airways of WT mice o day 7, there
were no increased numbers of neutrophils in BLM-
treated rac2−/− mice compared to saline treated mice on
day 7 (Figure 1B). For both total cells and neutrophils
there was a statistically significant difference between
BLM-treated WT and rac2−/− mice. The numbers of
macrophages increased in BLM-treated WT and rac2−/−
mice on day 7 (Figure 1C) but the number of lympho-
cytes showed only a trend towards increase by BLM in
both backgrounds (Figure 1D). There was no difference
between BLM-treated WT and rac2−/− mice in the
number of macrophages and lymphocytes in the BAL,
indicating that lack of Rac2 affects primarily neutrophil
accumulation in the airways of BLM-treated mice.
We next measured MPO activity in BAL samples. WT
mice treated with BLM showed higher levels of MPO in
BAL on day 3 and day 7 compared to saline-treated mice
(Figure 2A and B n = 5). Rac2−/− mice exhibited increased
MPO activity on day 3 but not on day 7 (Figure 2A
and B). There was no statistically significant difference
in MPO between BLM-treated WT and rac2−/− mice
on day 3 or day 7. Histological analysis of the lungs of
saline and BLM-treated WT and rac2−/− mice on day 7
showed diffuse inflammatory cell infiltration in both
groups of BLM-treated mice, but there were no clear
differences between the two groups in the pattern or
degree of inflammation (Figure 3).
We also examined the levels of matrix metalloprotein-
































































































































Figure 1 Rac2 mediates BLM-induced airway neutrophil infiltration. (A) Total cell counts, (B) neutrophils, (C) macrophages and (D)
lymphocytes in BAL samples at 3 and 7 days after intratracheal saline or bleomycin administration to WT and rac2−/− mice (n.s. not significant,
*p < 0.05, **p < 0.01, ***p < 0.001, n = 5).
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mice, on day 3 (Figure 2C). MMP-9 levels returned to
baseline by day 7 (Figure 2D). In contrast MMP-2 levels
were increased in both WT and rac2−/− mice on day 7,
but not day 3, and there was no difference in MMP-2
levels between BLM-treated WT and rac2−/− mice on
day 3 (Figure 2E and F).
In order to further understand the mechanisms for the
defect in neutrophil migration to the airways in rac2−/−
mice treated with BLM, we evaluated the levels of vari-
ous cytokines and chemokines in the BAL fluid. TNF
was increased in WT mice following BLM administra-
tion, but not in rac2−/− mice (Figure 4A, n = 5). IL-1β
and CXCL3/KC showed a trend towards an increase in
WT mice following BLM administration, but there were
no statistically significant differences between any of the
groups studies (Figure 4B and C, n = 5). CCL3/MIP-1α
showed similar pattern with TNF (Figure 4D, n = 5).
Finally CCL11/eotaxin and CXCL10/IP-10 were increasedin both WT and rac2−/− mice following BLM treatment
and there was no difference between BLM-treated WT
and rac2−/− mice (Figure 4E and F, n = 5).
Rac2 deficiency attenuates biological long-term
consequences of BLM-induced lung injury
BLM-induced lung injury in mice is characterized by the
development of extensive reversible fibrosis 15–20 days
after a single treatment [22]. Fibrosis alters lung physi-
ology and leads to significant morbidity and mortality in
this model, before the process resolves. Since rac2−/−
mice showed altered early inflammatory response after
lung injury, we next studied whether later events of
BLM injury, including mortality and fibrosis, were also
affected.
To understand the function of Rac2 in the long-term
effects of BLM-induced lung injury, WT and rac2−/−
mice were given BLM intratracheally and followed for
21 days. WT mice showed 70% mortality by day 21,
AC
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Figure 2 MPO and MMP in BAL fluid. MPO (A and B), MMP-9 (C and D) and MMP-2 (E and F) levels in the BAL fluid on day 3 (A, C, E) and 7
(B, D, F) after intratracheal saline or bleomycin administration to WT and rac2−/− mice. (n.s. not significant, *p < 0.05, **p < 0.01, ***p < 0.001, n = 5).
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(p < 0.005) (Figure 5). In order to further understand the
functional role of Rac2 in BLM-induced lung injury, we
analyzed lung physiology and markers of fibrosis in the
mice that survived until day 21.
WT mice that received BLM showed significantly in-
creased airway resistance and elastance compared to saline-
treated mice (p < 0.05) (Figure 6A and B, n = 8). In contrast,
rac2−/− mice that received BLM showed resistance and
elastance levels that were similar to rac2−/− mice receiving
saline. There was also significant difference in resistance
and elastance between BLM-treated WTand rac2−/− mice.
The mortality and pulmonary physiology results indi-
cate that BLM-induced injury is attenuated in rac2−/−
mice, and that in contrast to WT mice surviving to day21, the injury still present in the rac2−/− mice still sur-
viving to day 21 does not affect lung physiology.
Rac2 deficiency had no significant effect inflammation in
BLM-treated mice surviving to day 21
We also performed histological analysis of lungs from
surviving BLM-treated and saline-treated mice on day
21. Lungs were excised, fixed and then stained with
H&E for morphology and inflammatory cell infiltration
and PAS-D to identify mucin.
Saline-treated WT and rac2−/− mice (Figure 7A) showed
normal architectural pattern of airways and alveoli, with
an apparent increase in interstitial leukocytes evident in
rac2-/- mice. We hypothesize that the latter observation is





Figure 3 Histological analysis of BLM-induced lung injury on day 7. Representative images of H&E staining of lung sections 7 days after
intratracheal saline or bleomycin administration to WT and rac2−/− mice (in every condition 5 mice were analyzed by histology).
Figure 4 Cytokine/chemokine levels in BAL fluid. Levels of TNF (A), IL-1β (B), CXCL3/KC (C), CCL3/MIP-1α (D), CCL11/Eotaxin (E) and CXCL10/
IP-10 (F), were determined in BAL fluid 7 days after intratracheal saline or bleomycin administration to WT and rac2−/− mice. (n.s. not significant,
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 5).
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Figure 5 Rac2 deficiency decreases mortality in
bleomycin-induced pulmonary fibrosis. Survival curves shown
over 21 days for WT and rac2−/− mice receiving BLM or saline
(n = 13-22 per group).
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to support this conclusion. Lung parenchyma of WT
BLM-treated mice exhibited prominent perivascular,
peribronchiolar and intra-alveolar inflammation, with in-
creased numbers of alveolar macrophages (Figure 7A).
The lungs of rac2−/− BLM-treated mice showed a similar
picture except that interstitial inflammation often had a
more focal distribution. A semi-quantitative analysis (peri-
vascular, peribronchial and intra-alveolar infiltrates were
graded on a score of 0–3 for all the mice and these 3 num-
bers of every mouse were averaged and are presented as
the inflammation score) showed no significant difference
in inflammatory infiltrates between BLM-treated WT and
rac2−/− mice (Figure 7B).
We also stained the lungs with PAS-D to identify mucin
(Figure 8). WT BLM-treated mice displayed airway epithe-
lium exhibiting increased numbers of mucin-containing
epithelial cells consistent with goblet cell hyperplasia
(arrow, fuchsia colored cells). In contrast, rac2−/− BLM-
treated mice showed airway epithelium with reduced num-
bers of mucin-containing epithelial cells compared to WT
mice treated with BLM. In control saline-treated mice,Figure 6 Rac2 deficiency prevents BLM-included changes in pulmona
intratracheal saline or bleomycin administration to WT and rac2−/− mice (*pthere were essentially no mucin-containing epithelial cells
in WTand rac2−/− airway epithelia.
Effect of Rac2 deficiency on fibrosis in BLM-treated mice
surviving to day 21
To further assess the degree of fibrosis histologically, we
analyzed lung sections from WT and rac2−/− mice after
Masson’s Trichrome staining to evaluate collagen depos-
ition and measured total collagen in the lungs of these
mice. We also performed immunohistochemical analysis
with staining for αSMA and TGFβ.
WT and rac2−/− saline-instilled mice presented with
normal lung parenchyma with an expected minimal level
and distribution of collagen fibrils. In contrast, the lung
parenchyma of WTand rac2−/− BLM-treated mice showed
increased collagen deposition compared saline-treated
controls (arrows, Figure 9A lower panels). In general,
BLM-treated rac2−/− mice showed smaller patchy regions
of collagen deposition compared to BLM-treated WT
mice. However, evaluation of fibrosis by Ashcroft scoring
as done before [15] showed no significant difference be-
tween BLM-treated WTand rac2−/− mice (Figure 9B).
In order to determine fibrosis using biochemical ap-
proach, we estimated total lung collagen content using
the Sircol Dye Reagent and hydroxyproline content
using lung homogenates from saline and BLM-treated
WT and rac2−/− mice. We detected a significant increase
in total lung collagen content and in hydroxyproline
content in BLM-treated WT mice compared to saline-
treated mice (p < 0.05, n =6), while rac2−/− BLM-treated
mice did not show significant increase in lung collagen
or hydroxyproline content compared to saline-treated
rac2−/− animals (Figure 9C and D, n = 7-8 per group).
However, BLM-treated rac2−/− mice also showed no sta-
tistically significant difference in collagen or hydroxypro-
line content compared to BLM-treated WT mice.
To further study the role of Rac2 in pulmonary fibrosis
was also performed immunohistochemistry for αSMAry physiology. (A) Resistance and (B) elastance 21 days after






Figure 7 Histological analysis of BLM-induced lung injury. (A) Representative images from H&E staining of 21 days after intratracheal saline
or bleomycin administration to WT and rac2−/− mice (B) Inflammation score for saline and BLM-treated WT and rac2−/− mice 21 days following
saline or BLM administration (n.s. non-significant, *p < 0.05, n = 5-8).
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ences in αSMA and TGFβ staining between BLM-treated
WTand rac2−/− mice on day 21.
Discussion
Rac2 is a ras-related guanosine triphosphatase expressed
mainly in hematopoietic cells, and is a crucial molecule
regulating a diversity of neutrophil functions. We have
previously shown that disruption of the gene encoding
Rac2 significantly attenuated lung inflammation and in-
jury in an immune complex-mediated acute lung injury
model [13]. Injury in that model is mediated by Rac2
expression in hematopoietic cells. Although we did not
identify the exact cell(s) mediating Rac2-dependent in-
jury in that study, we speculated that neutrophils were
primarily responsible. Accumulation of neutrophils inthe BAL following immune complex-mediated acute
lung injury was decreased, as it was also decreased in
rac2−/− mice in the BLM injury model we present here.
We also showed here that there were differences in
MMP-9 levels in the BAL between BLM-treated WT
and rac2−/− mice as well as differences in certain cyto-
kine and chemokine levels. These inflammatory changes
correlated with changes in lung physiology. There was
however no significant difference in parenchymal inflam-
mation seen by histology and in fibrotic markers be-
tween surviving BLM-treated WT and rac2−/− mice on
day 21 after BLM treatment. Our study also showed a
large decrease in mortality of rac2−/− mice compared to
wild type mice following treatment with bleomycin. It is
not clear whether the changes in inflammation or





Figure 8 Analysis of mucin expression following BLM-induced lung injury. PAS-D staining of lung sections 21 days after intratracheal saline
or bleomycin administration to WT and rac2−/− mice (in each condition, 5–8 mice were analyzed by histology).
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identify the mechanisms leading to Rac2-mediated mor-
tality in the BLM model of lung injury. With the results
presented here our group has shown that rac2 gene defi-
ciency prevents or attenuates tissue injury in both acute
lung injury [13] and chronic lung injury (data presented
here) models.
BLM-induced lung injury develops in two phases in
mice. The first phase takes place over the first 9 days
after BLM administration, and is characterized by in-
flammation and accumulation of inflammatory cells in
the parenchyma and airways. The second fibrotic phase
starts on day 9, with the presence of pro-fibrotic media-
tors, and leads to the development of overt fibrosis [22].
In our model, we have shown an increase in MMP-9 on
day 3 along with an increase in the accumulation of neu-
trophils and macrophages in the airways on day 7 after
BLM administration to WT mice. The MMP-9 and neu-
trophil increase, but not the increase in macrophage
numbers, were absent from rac2−/− mice treated with
BLM. The exact reason for this is not clear at this time.
Neutrophil chemotaxis [23] and the subsequent accumu-
lation in the airways require Rac2 function, and the lack
of neutrophil accumulation may be an early event lead-
ing to these differences in rac2−/− mice.
Neutrophil accumulation and mediator release have
been implicated in the pathophysiology of BLM-induced
lung injury. Lack of CXCR2, the receptor for CXCL3/
KC, one of the main neutrophil chemotactic agents in
mice, resulted in decreased lung fibrosis along with
decreased accumulation of neutrophils in the airways
[24]. That study showed that CXCL3/KC levels increased6 h after BLM treatment and returned to normal by day
8. This may explain why we did not see significant
changes in CXCL3/KC levels in our mice when we ana-
lyzed them on day 7. It is interesting to note that in the
same study the numbers of neutrophils in the paren-
chyma, as assessed by the levels of MPO in the lung,
were not decreased, although tissue injury was de-
creased. In our study also we did not see a significant
difference in inflammatory cell infiltration in the lung
tissue on day 7 by histology between WT and rac2−/−
mice, although there was significant difference in the
numbers of neutrophils in the BAL on day 7. Transmi-
gration of neutrophils into the airways might facilitate
fibrosis through the release of mediators that can
activate TGFβ. For example it has been shown that lack
of elastase prevented TGFβ activation in the airways and
decreased the development of fibrosis following bleo-
mycin administration [20]. In our study we did not see
significant differences in TGFβ positive cells on day 21,
but we did not analyze TGFβ expression at earlier time
points to know if there were any differences.
We showed significant differences in TNF and CCL3/
MIP-1α between BLM-treated WT and rac2−/− mice.
Both of these mediators have been implicated in the
pathophysiology of bleomycin-induced injury. The de-
gree of bleomycin-induced injury correlates with TNF
upregulation in the lungs of different strains of mice
[25] and the presence of soluble TNF has been shown to
be required for the development of fibrotic lesions in the
lungs following bleomycin administration [26]. In addition
TNF has been shown to be mediating the increased








Figure 9 Rac2 deficiency and BLM-induced fibrosis. (A) Representative images of Masson’s trichrome staining of lung sections 21 days after
intratracheal saline or bleomycin administration to WT and rac2−/− mice (in every condition 5–8 mice were analyzed by histology). (B) Quantitation of
lung fibrosis using Ashcroft’s criteria (5–8 mice were analyzed per group). Total collagen (C) and hydroxyproline content (D) of lungs 21 days were
determined after intratracheal saline or bleomycin administration to WT and rac2−/− mice (n.s. not significant, *p < 0.05, n = 5-8).
Arizmendi et al. Respiratory Research 2014, 15:71 Page 10 of 13
http://respiratory-research.com/content/15/1/71mice [27]. CCL3/MIP-1α has been shown to be elevated
throughout the time course of bleomycin-induced lung
injury and is required for injury to develop [28]. CCL3/
MIP-1α recruits macrophages to the lung through the
interaction with CCR5 and may increase the expression
of TGFβ in the airways. Lack of these two inflammatorymediators in rac2−/− mice may be responsible for
the physiological and other changes described in this
manuscript.
A number of other mediators may also be involved in the
recruitment of neutrophils and the neutrophil-mediated












Figure 10 αSMA and TGFβ immunohistochemistry. Representative images showing immunostaining of αSMA, with arrows indicating the
presence of myofibroblasts (A), and TGFβ with arrows indicating TGFβ-positive leukocytes (B), in lung sections 21 days after intratracheal saline or
bleomycin administration to WT and rac2−/− mice (in every condition 5–8 mice were analyzed by histology).
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also induced by bleomycin in mouse lungs [30] and lung
injury was attenuated when IL-1β activity was decreased
[30]. In our study we only saw a trend towards de-
creased levels of IL-1β in rac2−/− mice compared to WT
mice following BLM treatment. Chemokines that acti-
vate CXCR3, such as CXCL10/IP-10 and CXCL9/MIG,
have a protective role and can limit fibrosis in the lungs
[31,32]. CCL11/eotaxin has also been shown to mediate
another pathway that leads to BLM-induced lung fibrosis
[33]. Our data indicate that these pathways may not be
affected in the absence of Rac2. There are finally also
other cytokines that have been shown to mediate BLM-
induced lung injury. For example, IL-17A is required for
BLM-induced fibrosis [29] and its main effect in the
model may be recruitment of neutrophils. Neutrophils inthe airways of mice with BLM injury produce IL-18, and
inhibition of IL-18 can prevent fibrosis [30]. IL-18 was also
increased in the lungs of patients with lung injury after re-
ceiving BLM. It would be interesting to also study changes
in these inflammatory mediators in BLM-treated Rac2
mice to better understand the mechanism of protection.
Other members of the Rho family of GTPases have also
been implicated in lung fibrosis. A RhoA inhibitor de-
creased accumulation of macrophages and neutrophils in
the airways of BLM-treated mice and also BLM-induced fi-
brosis [34]. In this case the effect is more likely through
inhibition of the proliferative effects of RhoA in lung fibro-
blasts [35]. In addition Rac1 expression in cutaneous fibro-
blasts in required for the development of BLM-induced
skin fibrosis [36]. This is an important family of signal-
ing molecules and there has been significant effort in
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increases the translational potential of these studies,
since these inhibitors may be proven to be valuable as
therapeutic options for lung fibrotic diseases.
The levels of MMP-2 and MMP-9 in the BAL fluid of
WT mice given BLM correlate with the levels in lung
tissues, and reportedly peak at day 4 [37]. In our case we
observed that the levels of MMP-9 were decreased com-
pared to WT responses on day 3 in rac2−/− mice, suggest-
ing that MMP-9 production was lacking in the knockout
mice. In our earlier study on acute lung injury, we deter-
mined that the main cell type responsible for generating
MMP-2 and MMP-9 in lung tissues was the tissue macro-
phage [13]. These findings indicate that macrophages may
be responsible for elevated production of MMP-2 and
MMP-9 in early stages of lung injury. Further studies are
needed to determine if reduced Rac2 activity in macro-
phages leads to reduced secretion of MMPs, or if reduced
recruitment of neutrophils to the airways of BLM-treated
rac2−/− mice results in decreased macrophage activation.
Macrophages have also been implicated in the patho-
physiology of BLM-induced injury in mice [21,38]. In
our study we did not see a difference in macrophage
accumulation in the airways in the early stages of BLM-
induced injury in rac2−/− mice. However, Rac2 is important
for macrophage function, and it is possible that decreased
activity and or altered activation status of the recruited
macrophages may have a role in the effects we describe. A
role for Rac1 in the inflammatory, but not fibrotic, phase of
asbestos-induced lung injury in mice has been shown in a
mouse strain with conditional, myeloid-specific gene dele-
tion of Rac1 [39]. This observation suggests that granulo-
cyte/macrophage-expressed Rac1 regulates inflammatory
processes, but has little impact on fibrotic lesions arising
from asbestos exposure. Although a different model was
used in our study, our findings show an additional role for
Rac2 in lung physiology and mortality associated with fibro-
sis, which has not been reported before.Conclusions
This manuscript shows that rac2 deficiency decreases
BLM-induced mortality from 70% in wild type mice to
less than 30% in Rac2 knockout mice. Rac2 activation
also plays an important role in BLM-induced alterations
in respiratory physiology and may also mediate the de-
velopment of early airway inflammation in response to
inhaled BLM. We conclude that Rac2 mediates many
physiological changes seen in the lungs that may be re-
lated to BLM-induced mortality.
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